Skip to main content
. 2021 Aug 31;12:5195. doi: 10.1038/s41467-021-25506-6

Fig. 5. Therapeutic effect of heterologous vaccine in syngeneic tumor model expressing ovalbumin.

Fig. 5

a–e C57BL/6J mice were injected s.c. with E.G7-OVA cells and vaccinated with KISIMA-OVA (K) s.c. or VSV-GP-OVA (V) i.v. on days indicated in schematic (a). 200 µg αPD-1 antibody was given i.v. twice weekly and blood was drawn for tetramer analysis as shown (n = 7). b Tumor growth and (c, d) survival is depicted with red numbers indicating long-term remissions within a group. Pairwise Log-rank test was performed (*p < 0.05; **p < 0.01; ***p < 0.001). e Frequency (mean ± SEM) of OVA-specific CD8+ T cells in circulation is shown. One-way ANOVA with Tukey’s multiple comparison was performed and significance displayed only for each vaccinated group vs. mock (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). The experiments (b–d) were repeated once with i.m. application of VSV-GP-OVA. Study (e) was performed once. Source data and p-values are provided in the Source Data File.